Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
Scientists have developed a new drug that targets the KRAS protein, which is responsible for most pancreatic cancers and was previously considered 'undruggable.' This breakthrough has shown potential to nearly double survival rates for patients with advanced stages of the disease.
Why it matters
Pancreatic cancer has historically had extremely low survival rates; targeting the KRAS mutation represents a major shift in oncology and patient prognosis.
For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.
The article reports on medical advancements and clinical research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in